A detailed history of Jump Financial, LLC transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 46,768 shares of MIRM stock, worth $2.16 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
46,768
Previous 20,478 128.38%
Holding current value
$2.16 Million
Previous $700,000 160.43%
% of portfolio
0.04%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$33.68 - $44.74 $885,447 - $1.18 Million
26,290 Added 128.38%
46,768 $1.82 Million
Q2 2024

Aug 14, 2024

BUY
$23.57 - $34.85 $482,666 - $713,658
20,478 New
20,478 $700,000
Q4 2023

Oct 21, 2024

SELL
$27.14 - $34.93 $2.15 Million - $2.77 Million
-79,218 Reduced 90.66%
8,166 $241,000
Q4 2023

Feb 07, 2024

SELL
$27.14 - $34.93 $2.15 Million - $2.77 Million
-79,218 Reduced 90.66%
8,166 $241,000
Q3 2023

Oct 21, 2024

BUY
$24.63 - $32.85 $1.85 Million - $2.46 Million
75,024 Added 606.99%
87,384 $2.76 Million
Q3 2023

Nov 07, 2023

BUY
$24.63 - $32.85 $1.85 Million - $2.46 Million
75,024 Added 606.99%
87,384 $2.76 Million
Q2 2023

Oct 21, 2024

SELL
$23.51 - $30.09 $190,854 - $244,270
-8,118 Reduced 39.64%
12,360 $319,000
Q2 2023

Aug 07, 2023

BUY
$23.51 - $30.09 $290,583 - $371,912
12,360 New
12,360 $319,000
Q4 2022

Feb 13, 2023

SELL
$17.59 - $23.83 $82,338 - $111,548
-4,681 Reduced 15.77%
25,000 $487,000
Q3 2022

Nov 07, 2022

BUY
$19.98 - $29.44 $169,450 - $249,680
8,481 Added 40.0%
29,681 $624,000
Q2 2022

Aug 09, 2022

BUY
$18.42 - $27.5 $1,842 - $2,750
100 Added 0.47%
21,200 $413,000
Q1 2022

May 12, 2022

BUY
$15.5 - $23.93 $327,050 - $504,923
21,100 New
21,100 $464,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.7B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.